PBPK modeling to support assessment of bioequivalence of locally acting drugs in the gastrointestinal tract

The summary for the PBPK modeling to support assessment of bioequivalence of locally acting drugs in the gastrointestinal tract grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food and Drug Administration, which is the U.S. government agency offering this grant.

PBPK modeling to support assessment of bioequivalence of locally acting drugs in the gastrointestinal tract: One specific objective of this project is to identify product quality attributes (formulation variables) and physiological or pathological variables that can influence the local and systemic bioavailability of locally-acting drug products in the gastrointestinal (GI) tract. Another specific objective of this project is to integrate predictive dissolution and PBPK models to assess whether they can support a demonstration of BE for generic locally-acting drugs in the GI tract. A general objective of this project is to assess whether model-integrated approaches using predictive in vitro data (e.g., dissolution data) may represent an alternative to comparative clinical end point BE studies when evaluating the BE of locally-acting drug products in the GI tract. Ideally, the proposal should include, at a minimum, plans for:1) how to leverage currently available or to-be-developed (new) in vitro methodologies for drug release and dissolution when developing a PBPK model that utilizes the in vitro data to simulate and predict differences in product performance based upon formulation differences, including excipient effects in vivo. The proposed in vitro dissolution method is expected to utilize conditions that are representative of the physiological and/or pathological conditions at the site of action for the selected drug products.2) how to (i.e., what data to use to) estimate between- and within-subject variability, as it is desired that the proposed PBPK model would be a part of virtual BE framework. It is expected that these variabilities would stem from variabilities in physiological factors, as well as the interaction/correlation between formulation-physiological factors. Strategies (specific approaches) for estimating the variabilities, particularly within-subject variability, and for simulating the effect of that variability on virtual BE studies should be clearly laid out, detailing a plan to evaluate these approaches.3) how to assess model performance and credibility in predicting the local concentration of locally acting drug(s) in the GI tract. It is desirable that the verification and validation plan is included in the proposal.4) how the virtual BE simulations would be conducted, described in detail (addressing both, systemic and local concentrations), including how the data will be analyzed, preferably within the modeling platform.5) the dissemination of the outcomes of the research effort (e.g., presentations at scientific conferences, workshops, meetings and publications in scientific journals).6) how to deliver the final developed model to the FDA Office of Generic Drugs (OGD), at a minimum, and preferably made public. Open-source code is preferable, but not required.

Federal Grant Title:	PBPK modeling to support assessment of bioequivalence of locally acting drugs in the gastrointestinal tract
Federal Agency Name:	Food and Drug Administration (HHS-FDA)
Grant Categories:	Consumer Protection Health Science and Technology
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-FD-22-012
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.103
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 31st, 2022
Original Application Deadline:	March 31st, 2022
Posted Date:	January 12th, 2022
Creation Date:	January 12th, 2022
Archive Date:	April 30th, 2022
Total Program Funding:	$500,000
Maximum Federal Grant Award:	$600,000
Minimum Federal Grant Award:	$50,000
Expected Number of Awards:	2
Cost Sharing or Matching:	No
Last Updated:	January 12th, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses
Additional Information on Eligibility: Eligible OrganizationsHigher Education InstitutionsPublic/State Controlled Institutions of Higher EducationPrivate Institutions of Higher EducationThe following types of Higher Education Institutions are always encouraged to apply for FDA support as Public or Private Institutions of Higher Education:o Hispanic-serving Institutionso Historically Black Colleges and Universities (HBCUs)o Tribally Controlled Colleges and Universities (TCCUs)o Alaska Native and Native Hawaiian Serving Institutionso Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)Nonprofits Other Than Institutions of Higher EducationNonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)For-Profit OrganizationsSmall BusinessesFor-Profit Organizations (Other than Small Businesses)GovernmentsState GovernmentsCounty GovernmentsCity or Township GovernmentsSpecial District GovernmentsIndian/Native American Tribal Governments (Federally Recognized)Indian/Native American Tribal Governments (Other than Federally Recognized)U.S. Territory or PossessionOtherIndependent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesNative American Tribal Organizations (other than Federally recognized tribal governments)Faith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Institutions)Foreign InstitutionsNon-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the HHS Grants Policy Statement, are allowed.
Link to Full Grant Announcement: FULL ANNOUNCEMENT
Grant Announcement Contact: Shashi Malhotra
Grants Management Specialist
Phone 2404027592
[email protected]
Similar Government Grants: • Renewal Application: Kidney Health Initiative (R18) Clinical Trials Optional; • Renewal Application: Increasing the Quality and Efficiency of Clinical Trials (U18) Clinic...; • Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, a...; • Development and Maintenance of the Animal Food Regulatory Program Standards (U19) Clinical...; • Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biologic...; • Support for Small Scientific Conference Grant Program; • Cooperative Agreement to Support the World Health Organization (WHO) International Program...; • Clinical Studies of Safety and Effectiveness of Orphan Products
More Grants from the Food and Drug Administration: • Renewal Application: Kidney Health Initiative (R18) Clinical Trials Optional; • Renewal Application: Increasing the Quality and Efficiency of Clinical Trials (U18) Clinic...; • Convener and Organizer of Activities and Engagements Related to Processes, Surveillance, a...